SOUTH SAN FRANCISCO, Calif., July 26, 2017 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2017 financial results on Tuesday, August 8, 2017, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, August 8, 2017, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company's financial results and provide a general business update.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 61862496.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe Investor Relations 415-365-5737 [email protected]


Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
First Western Ship Transits Strait of Hormuz Since Iran War Began
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 



